Business Wire

Open-Source Healthcare App Released Globally for Free

Share

Traction on Demand and Thrive Health announced free, global availability for a new open-source mobile application for healthcare providers that are fighting the COVID-19 outbreak, available here on Salesforce AppExchange—the world’s leading enterprise cloud marketplace. The Traction Thrive Critical Care Resource Management application, built on the Salesforce platform, is designed to view, track and allocate critical healthcare personnel, personal protective equipment, ventilator availability, and other critical supplies in real-time.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200409005127/en/

“Our partner community is making available an open-source mobile solution to help scale the ability to respond to the crisis with critical resources,” said Rob Acker, CEO of Salesforce.org. “Our hope is that nonprofits, governments, and health systems around the world will benefit from this platform designed to offer agility and flexibility for their individual needs during this crucial time.”

The app is designed to enable governments and healthcare providers to better understand the impact of the COVID-19 virus at a local level, and to allocate resources to save lives and ease pressure on healthcare workers. Whereas hospitals can install their own independent version, the app can also be implemented by healthcare systems enabling them to get an at-a-glance view of their full network’s utilization and capacity.

“This app helps healthcare workers to be better armed with what they need to save lives and stay protected,” said Greg Malpass, Founder and CEO of Traction on Demand, which designed and built the system. "After a successful engagement of 26 hospitals within the first week of launch, we've decided to make this app available globally on AppExchange free of charge. It’s the right thing to do."

The app was built on the Salesforce platform, enabling health organizations to implement and scale rapidly. Traction Thrive is customizable by healthcare providers, scalable without any new data centers, accessible from permanent and temporary facilities worldwide, and portable by practitioners across devices.

Canadian healthcare technology firm Thrive Health identified the need for real-time worker and equipment tracking, and conceptualized the solution in partnership with Traction on Demand.

"In a time of crisis, it is crucial to be able to track your people and critical supplies in real time, so they can be allocated efficiently and effectively to save lives and ease pressure on the system," says David Helliwell, Co-Founder and CEO of Thrive Health.

The Traction Thrive Critical Care Resource Management app has three functions:

  • Enables healthcare workers to specify which workers, ventilators and personal protective equipment they have while also showing each facility’s current occupancy and resource capacity.
  • Serves as a communication hub between healthcare providers within a site or across regions.
  • Offers advanced reporting capabilities for hospitals and regional health leadership.

“The severity of outcomes for this outbreak now largely depends on ensuring that hospitals and healthcare workers have the resources they need to treat all infected patients while keeping themselves safe,” said Dr. Ashwini Zenooz, Chief Medical Officer of Healthcare and Life Sciences at Salesforce. “ We're operating in real-time. This means organizations need hyper-local insight into the COVID-19 outbreak so they can allocate supplies and resources accordingly.”

The Traction Thrive Critical Resource Management app was built by Traction on Demand and Thrive Health. To learn more, visit https://appexchange.salesforce.com/appxListingDetail?listingId=a0N3A00000FMvlIUAT.

Salesforce, AppExchange, Salesforce.org and others are among the trademarks of salesforce.com, inc.

About Traction on Demand

Traction on Demand is one of North America's largest dedicated Salesforce consulting and app development firms. The company helps commercial and nonprofit organizations design, develop and implement Salesforce technology. Traction on Demand is a proud B Corporation. Visit tractionondemand.com for more information.

About Thrive Health

Thrive Health is a software company founded with a mission to improve the delivery of healthcare in Canada and around the world. The company is helping millions of Canadians to track their COVID-19 symptoms at thrive.health/covid19-app using the #1 medical app in Google Play and Apple App Store. Visit thrive.health for more information.

Contact information

For further information:
UK
TopLine Comms
Jodie Brazier, Comms Consultant
tractionondemand@toplinecomms.com
+44 (0) 7487 514511

Europe
Traction on Demand
Kelsi Tsatouhas, PR Manager
kelsi@talkshopmedia.com
1-604-786-2273

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Closer Collaboration between the EUIPO and EURid to Benefit SMEs25.5.2020 13:30:00 CESTPress release

The European Union Intellectual Property Office (EUIPO) and EURid, the domain name registry for the .eu, .ею and .ευ top-level domains, are set to intensify collaboration to support trade mark and domain name applicants and owners, particularly small and medium enterprises (SMEs). This collaboration will support users of the EU IP system, particularly startups, by helping them to obtain trade mark and domain name protection in a joined-up manner, so they can secure their brands from the very beginning of their business journey. At present, EU trade mark applicants are advised whether their trade mark is available as a .eu domain name at the end of the online application process at EUIPO. Applicants and holders can also set up alerts to be informed once a .eu domain name that matches their trade mark is registered. Under a new work programme agreed jointly by the two organisations, the EUIPO and EURid will explore the possibility of implementing a reciprocal process when a .eu domain na

TIP Trailer Services Announces Appointment of New CFO25.5.2020 10:05:00 CESTPress release

TIP Trailer Services, a portfolio company of I Squared Capital, has appointed Hans van Lierop as Chief Financial Officer and management board member. Hans started as CFO for TIP from Monday, 18th of May 2020 and is based in TIP’s international headquarters in Amsterdam, the Netherlands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200525005042/en/ Hans van Lierop, appointed CFO of TIP Trailer Services (Photo: Business Wire) “I am looking forward to joining TIP’s senior leadership team and leading its Finance organisation and look forward to contributing to TIPs future success. ” Hans van Lierop commented. Hans van Lierop joins TIP with broad international experience from different industries in Europe and Africa. He has held financial leadership roles in Diageo, Airtel and Massmart Walmart. Most recently, Hans Van Lierop was CFO of Massmart Walmart, a South African retail and wholesale distributor with a turnover of US$ 7

Teva Presented New Data at the European Academy of Neurology Congress Evaluating the AJOVY ® (fremanezumab) Experience in Populations with Difficult-to-Treat Migraine25.5.2020 08:00:00 CESTPress release

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) presented a wide range of important new data on AJOVY® (fremanezumab) and the societal and economic impact of migraine in Europe at the 6th Congress of the European Academy of Neurology (EAN). This year’s EAN congress was a virtual meeting due to the global coronavirus pandemic. The fremanezumab data included pooled analyses of the AJOVY Phase 3 clinical trials (FOCUS, HALO-episodic migraine (EM) and HALO-chronic migraine (CM)) which focused on the safety, efficacy and improved quality-of-life for patients experiencing difficult-to-treat migraine. Post-hoc analyses were also evaluated in patients who may experience challenges when managing their migraine due to comorbidities. Migraine creates a significant disease and economic burden. With more than one billion people impacted globallyi, migraine is the second leading global cause of years lived with disabilityii and annual costs of the disease in the U.S. and EU are $200 billio

JEOL: Release of a New Schottky Field Emission Scanning Electron Microscope JSM-IT80025.5.2020 08:00:00 CESTPress release

JEOL Ltd. (TOKYO:6951) (President & COO Izumi Oi) announces the release of a new Schottky field emission scanning electron microscope, JSM-IT800 in May 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200524005002/en/ JSM-IT800 (Photo: Business Wire) Development Background Scanning electron microscopes (SEMs) are used in various fields, such as nanotechnology, metals, semiconductors, ceramics, medicine, and biology. As SEM applications are expanding from research and development to quality control and product inspection at manufacturing sites, SEM users are in need of faster high-quality data acquisition and simple compositional information confirmation with seamless operation. To meet these demands, the JSM-IT800, with the Intelligence Technology (IT) platform, incorporates our In-lens Schottky Plus field emission electron gun for high resolution imaging to fast elemental mapping, and an innovative electron optical cont

Ipsen: New Surveys Show Over 80% of Patients with Spasticity and Cervical Dystonia Treated with Botulinum Toxin-A Experience Debilitating Symptom Recurrence23.5.2020 07:00:00 CESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today presents the results of two patient surveys. The surveys involved over 400 respondents from five countries, living with spasticity or cervical dystonia and receiving botulinum neurotoxin type A (BoNT-A) injections. The results show that over 80% of respondents experienced debilitating symptom recurrence, and revealed that a lack of long-lasting symptom control between injections has a profound impact on the personal and professional lives of patients.1-4 “The results from these two important patient surveys provide significant insight into the real-life burden of the two conditions; however, they also highlight a worrying disconnect between patients’ treatment expectations and their actual experience. The findings, which build on our growing understanding of spasticity and cervical dystonia, provide us with the potential to unlock meaningful changes in clinical practice,” said Dr Alberto Esquenazi, Department of Physical Medicine

U.S. FDA Approves Takeda’s ALUNBRIG ® (brigatinib) as a First-Line Treatment Option for Patients Diagnosed with Rare and Serious Form of Lung Cancer22.5.2020 22:30:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) approved ALUNBRIG (brigatinib) for adult patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. This approval expands ALUNBRIG’s current indication to include the first-line setting. ALUNBRIG is a potent and selective next-generation tyrosine kinase inhibitor (TKI) designed to target ALK molecular alterations. “We’re extremely proud of the positive results ALUNBRIG has shown for newly diagnosed ALK+ NSCLC patients, particularly those with brain metastases,” said Teresa Bitetti, President, Global Oncology Business Unit, Takeda. “Through a robust clinical development program and ongoing investigations across the NSCLC treatment landscape, Takeda is committed to uncovering solutions for people living with devastating forms of lung cancer in need of new options. We believe this approva

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom